We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+12.86%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-13.81%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Expedia Group
EXPE
|
+$752K |
| 2 |
Gartner
IT
|
+$681K |
| 3 |
Trane Technologies
TT
|
+$681K |
| 4 |
Eaton
ETN
|
+$660K |
| 5 |
Prologis
PLD
|
+$658K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$778K |
| 3 |
IDEX
IEX
|
+$731K |
| 4 |
Tesla
TSLA
|
+$719K |
| 5 |
Yum China
YUMC
|
+$714K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Vaxcyte
PCVX
$7.65B
| $96K | 0.06% |
1,528
-355
| -19% | -$18.4K |
|
|
ETNB
377
DELISTED
89bio
ETNB
| $95.9K | 0.06% |
8,588
+3,969
| +86% | +$36.5K |
|
|
BLTE
378
Belite Bio
BLTE
$6.11B
| $95.9K | 0.06% |
+2,096
| New | +$80.6K |
|
379
Recursion Pharmaceuticals
RXRX
$1.58B
| $95.8K | 0.06% |
9,715
-317
| -3% | -$2.26K |
|
380
Biomea Fusion
BMEA
$88.2M
| $95.7K | 0.06% |
6,589
+4,046
| +159% | +$49.2K |
|
381
MacroGenics
MGNX
$233M
| $95.7K | 0.06% |
+9,944
| New | +$68.7K |
|
|
DVAX
382
DELISTED
Dynavax Technologies
DVAX
| $95.4K | 0.06% |
6,823
-1,008
| -13% | -$14K |
|
|
SLRN
383
DELISTED
ACELYRIN
SLRN
| $94.9K | 0.06% |
+12,717
| New | +$109K |
|
|
DAWN
384
DELISTED
Day One Biopharmaceuticals
DAWN
| $94.8K | 0.06% |
6,492
-847
| -12% | -$10.3K |
|
385
Sana Biotechnology
SANA
$882M
| $94.7K | 0.06% |
+23,203
| New | +$85.5K |
|
386
Phathom Pharmaceuticals
PHAT
$928M
| $94.7K | 0.06% |
10,367
+2,623
| +34% | +$22.6K |
|
387
Crinetics Pharmaceuticals
CRNX
$8.88B
| $94.4K | 0.06% |
2,654
-2,195
| -45% | -$67.3K |
|
|
ITOS
388
DELISTED
iTeos Therapeutics
ITOS
| $94.1K | 0.06% |
8,596
+1,530
| +22% | +$15.2K |
|
389
Scholar Rock
SRRK
$5.88B
| $93.8K | 0.06% |
+4,988
| New | +$62K |
|
390
Zentalis Pharmaceuticals
ZNTL
$332M
| $93.8K | 0.06% |
6,189
+2,177
| +54% | +$31.8K |
|
|
ALPN
391
DELISTED
Alpine Immune Sciences Inc
ALPN
| $93.5K | 0.06% |
+4,904
| New | +$68.1K |
|
392
Oric Pharmaceuticals
ORIC
$1.17B
| $92.8K | 0.06% |
+10,085
| New | +$72.9K |
|
393
Vir Biotechnology
VIR
$1.46B
| $92.8K | 0.06% |
9,221
+5,419
| +143% | +$49.5K |
|
|
TERN
394
DELISTED
Terns Pharmaceuticals
TERN
| $92.7K | 0.06% |
14,287
+5,883
| +70% | +$31.1K |
|
395
Xencor
XNCR
$1.45B
| $92.6K | 0.06% |
4,363
+641
| +17% | +$12.2K |
|
396
Kymera Therapeutics
KYMR
$8.66B
| $92.6K | 0.06% |
3,638
-199
| -5% | -$3.56K |
|
397
Alector
ALEC
$169M
| $92.4K | 0.06% |
11,573
-1,258
| -10% | -$7.45K |
|
398
Madrigal Pharmaceuticals
MDGL
$12.6B
| $91.9K | 0.06% |
397
+9
| +2% | +$1.57K |
|
399
Disc Medicine
IRON
$2.81B
| $91.8K | 0.06% |
1,589
-425
| -21% | -$21.8K |
|
400
Immunovant
IMVT
$7.93B
| $91.6K | 0.06% |
2,174
-2,473
| -53% | -$91K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2023 Portfolio in Review
As of Q4 2023, Virtus ETF Advisers held 474 positions worth $158M, down 4.3% from $165M the previous quarter. Its ten largest holdings account for 5.6% of the portfolio.
Virtus ETF Advisers withdrew a net $21.7M in Q4 2023, closing 49 positions and reducing 231 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $854K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Financials.
Against the trend, Virtus ETF Advisers opened a new position in Expedia Group worth $932K.
- Virtus ETF Advisers's largest Q4 2023 buy was Expedia Group: 6,139 shares worth $932K.
- Virtus ETF Advisers added most to Pioneer Natural Resource Co. in Q4 2023, an estimated $535K increase.
- Virtus ETF Advisers's biggest Q4 2023 reduction was VICI Properties, cutting an estimated $659K.
- Virtus ETF Advisers fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $854K.
- Virtus ETF Advisers's ten largest holdings make up 5.6% of its $158M portfolio in Q4 2023.
- Virtus ETF Advisers opened 40 new positions and closed 49 in Q4 2023.
- Virtus ETF Advisers's portfolio value fell 4.3% quarter-over-quarter to $158M.
Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.